论文部分内容阅读
本文对比了氟氧头孢（ｆｌｏｍｏｘｅｆ，ＦＭＸ）与对照药头孢美唑（ｃｅｆｍｅｔａｚｏｎｅ，ＣＭＺ）对呼吸道感染患者的临床疗效和不良反应，尽管随机分组中ＦＭＸ组患者年龄偏大，基础疾病相对较多，但ＦＭＸ组痊愈率为６３．６％，有效率为９０．９％，与ＣＭＺ组无显著差异；尤其ＦＭＸ对金黄色葡萄球菌感染最有效（１００％痊愈），细菌清除率（１００％）亦比ＣＭＺ组（８８．９％）高，未见任何不良反应，从而提示ＦＭＸ为一安全有效的新抗生素。
This article compared the clinical efficacy and adverse reactions of flomoxef (FMX) and the control drug cefmetazone (cefmetazole) (CMZ) in patients with respiratory tract infections. Although patients in the FMX group were older and had more underlying diseases, However, the cure rate of FMX group was 63.6% and the effective rate was 90.9%, which was not significantly different from that of CMZ group. In particular, FMX was the most effective (100%) for Staphylococcus aureus infection and bacterial clearance rate (100%) Higher than CMZ group (88.9%), no adverse reactions, suggesting that FMX is a safe and effective new antibiotics.